Avicanna

Avicanna FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Avicanna (AVCN.TO) as of Nov 21, 2026 is 50.53 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 81.53 % — a change of -38.02% (lower).

FCF Conversion

50.53 %

YoY

-38.02%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Avicanna is 2025 50.53 % . FCF Conversion Rate (FCF/EBITDA) of Avicanna was 2024 81.53 % . It decreases by -38.02% lower compared to the previous year.

The Avicanna FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
125.50 CAD
Jan 1, 2019
121.28 CAD
Jan 1, 2020
46.95 CAD
Jan 1, 2021
74.23 CAD
Jan 1, 2022
50.91 CAD
Jan 1, 2023
22.44 CAD
Jan 1, 2024
81.53 CAD
Jan 1, 2025
50.53 CAD
The Avicanna FCF Conversion history
YEARFCF ConversionYoY
50.53 %-38.02%
81.53 %+263.34%
22.44 %-55.93%
50.91 %-31.41%
74.23 %+58.12%
46.95 %-61.29%
121.28 %-3.36%
125.50 %+23.31%
101.78 %-94.28%
1,779.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Avicanna Stock analysis

What does Avicanna do? Avicanna Inc is a Canadian biopharmaceutical company specializing in the research, development, and manufacturing of medical marijuana products. The company was founded in 2016 by its president and CEO Aras Azadian, who has extensive experience in the pharmaceutical and biotechnology industry. The company is based in Toronto, Canada and also operates in Colombia and Switzerland. Avicanna has several subsidiaries, including Santa Marta Golden Hemp, which operates its cultivation business in Colombia. Avicanna's business model is focused on producing medical marijuana products that have better efficacy and tolerability than conventional products. The company uses a specialized process called PhytoVista™ to isolate and extract the active ingredients in plant extracts. Avicanna operates in various sectors, including the manufacturing and marketing of medical marijuana products, research and development of effective medical treatments, and collaboration with healthcare facilities and government agencies in marijuana regulation. The company offers a variety of products, including different types of hemp oil, CBD products, and pharmaceutical products such as Rho PhytoTM and Pura EarthTM. These products all share the common approach of providing patients with better, more effective, and tolerable treatment options. Rho PhytoTM is a patented medical marijuana product by Avicanna, derived from a specific cannabis strain called ACMPR. This product is approved in Canada and available as an oral solution and syringe. Rho PhytoTM is specifically tailored to meet the needs of patients with neurodegenerative diseases and has proven to be effective. Pura EarthTM is a herbal remedy derived from the medical marijuana plant and is intended to be used as an alternative medicine for pain and inflammation. In addition to manufacturing medical marijuana products, the company also conducts intensive research and development to develop medications based on synthetic cannabinoids. These substances have the potential to help patients with various conditions such as multiple sclerosis, epilepsy, and tumor diseases. Avicanna also has partnerships with various healthcare facilities and government agencies to advance the regulation of medical marijuana and ensure the safety and efficacy of these products. In summary, Avicanna is an innovative biopharmaceutical company specializing in the manufacturing and marketing of medical marijuana products. The company serves various areas within the marijuana industry, including the production of medical products, research and development, and regulation of marijuana products. With an extensive product range and a strong research and development department, Avicanna is well positioned to continue growing and developing more innovative products in the coming years. Avicanna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Avicanna stock

FCF Conversion Rate (FCF/EBITDA) of Avicanna is 50.53 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Avicanna changed from 81.53 % to 50.53 %, representing a -38.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Avicanna since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Avicanna with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Avicanna

All Key Metrics — Avicanna